keyword
MENU ▼
Read by QxMD icon Read
search

Cancer death dying chemotherapy

keyword
https://www.readbyqxmd.com/read/27923361/epidemiology-of-breast-cancer-retrospective-study-in-the-central-african-republic
#1
Augustin Balekouzou, Ping Yin, Christian Maucler Pamatika, Ghose Bishwajit, Sylvain Wilfrid Nambei, Marceline Djeintote, Barbara Esther Ouansaba, Chang Shu, Minghui Yin, Zhen Fu, Tingting Qing, Mingming Yan, Yuanli Chen, Hongyu Li, Zhongyu Xu, Boniface Koffi
BACKGROUND: Breast cancer is recognised as a major public health problem in developing countries; however, there is very limited evidence about its epidemiology in the Central African Republic. The aim of this study was to investigate the epidemiological and histopathological characteristics of breast cancer in Bangui. METHODS: This is a retrospective study based on the data collected from pathological anatomy records from 2003 to 2015 in Bangui. A questionnaire was designed to collect information and data was analysed using descriptive and inferential statistical methods...
December 7, 2016: BMC Public Health
https://www.readbyqxmd.com/read/27897039/use-of-nanotechnology-for-improved-pharmacokinetics-and-activity-of-immunogenic-cell-death-inducers-used-in-cancer-chemotherapy
#2
Martyna Janicka, Jerzy Gubernator
Immunogenic cell death inducers (ICD inducers) are a diverse group of therapeutic molecules capable of eliciting an adaptive immune response against the antigens present on the surface of dying cancer cells. Most of these molecules suffer from low bioavailability, high toxicity and poor pharmacokinetics which limit their application. It is believed that nanotechnology, in particular nano-sized nanocarriers, can address most of the issues that limit the use of ICD inducers. Area covered: The mechanism of action of ICD inducers and their limitations is discussed...
December 8, 2016: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/27867526/characteristics-of-patients-with-haematological-and-breast-cancer-1996-2009-who-died-of-heart-failure-related-causes-after-cancer-therapy
#3
Vincent L Versace, Narelle M Berry, Munir H Chowdhury, Shahid Ullah, Alexandra L McCarthy, John J Atherton, Bogda Koczwara, David Roder, Robyn A Clark
AIMS: To describe the characteristics and time to death of patients with breast or haematological cancer who died of heart failure (HF) after cancer therapy. Patients with an index admission for HF who died of HF-related causes (IAHF) and those with no index admission for HF who died of HF-related causes (NIAHF) were compared. METHODS AND RESULTS: We performed a linked data analysis of cancer registry, death registry, and hospital administration records (n = 15 987)...
December 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27858564/preparing-for-value-based-payment-a-stepwise-approach-for-cancer-centers
#4
Kerin B Adelson, Salimah Velji, Kavita Patel, Basit Chaudhry, Catherine Lyons, Rogerio Lilenbaum
Most cancer centers are ill-equipped to pursue value-based payment (VBP) because of limited information on their population's cost of care. Herein, we outline the stepwise approach used by Smilow Cancer Hospital at Yale-New Haven in our pursuit of better value care. First, we addressed institutional barriers. A move toward value required demonstration to Yale-New Haven Health System leadership that OCM would improve patient care, fund new infrastructure, and provide the opportunity to gain experience with VBP without a major threat to the financial stability of the health system...
October 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27858180/irinotecan-monotherapy-as-third-line-treatment-for-advanced-gastric-cancer-refractory-to-fluoropyrimidines-platinum-and-taxanes
#5
Takashi Nishimura, Satoru Iwasa, Kengo Nagashima, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku
BACKGROUND: Because standard chemotherapy for advanced gastric cancer consists of oral fluoropyrimidines plus platinum as first-line therapy, with paclitaxel plus ramucirumab as the second line, irinotecan is usually positioned as third-line chemotherapy in clinical practice in Japan. METHODS: A retrospective evaluation was conducted to determine the efficacy and safety of irinotecan as third-line chemotherapy for advanced gastric cancer in patients refractory or intolerant to fluoropyrimidines, platinum, and taxanes...
November 17, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/27821313/systematic-versus-on-demand-early-palliative-care-a-randomised-clinical-trial-assessing-quality-of-care-and-treatment-aggressiveness-near-the-end-of-life
#6
Marco Maltoni, Emanuela Scarpi, Monia Dall'Agata, Stefania Schiavon, Claudia Biasini, Carla Codecà, Chiara Maria Broglia, Elisabetta Sansoni, Roberto Bortolussi, Ferdinando Garetto, Luisa Fioretto, Maria Teresa Cattaneo, Alice Giacobino, Massimo Luzzani, Giovanna Luchena, Sara Alquati, Silvia Quadrini, Vittorina Zagonel, Luigi Cavanna, Daris Ferrari, Paolo Pedrazzoli, Giovanni Luca Frassineti, Antonella Galiano, Andrea Casadei Gardini, Manlio Monti, Oriana Nanni
AIM: Early palliative care (EPC) in oncology has shown sparse evidence of a positive impact on patient outcomes, quality of care outcomes and costs. PATIENTS AND METHODS: Data for this secondary analysis were taken from a trial of 207 outpatients with metastatic pancreatic cancer randomly assigned to receive standard cancer care plus on-demand EPC (standard arm) or standard cancer care plus systematic EPC (interventional arm). After 20 months' follow-up, 149 (80%) had died...
November 4, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27761580/decreased-platelet-reactivity-in-patients-with-cancer-is-associated-with-high-risk-of-venous-thromboembolism-and-poor-prognosis
#7
Julia Riedl, Alexandra Kaider, Christine Marosi, Gerald W Prager, Beate Eichelberger, Alice Assinger, Ingrid Pabinger, Simon Panzer, Cihan Ay
Platelets are suggested to play a crucial role in cancer progression and the prothrombotic state of cancer patients. Here, we aimed to examine the activation status of platelets in cancer patients and investigate their association with risk of death and occurrence of venous thromboembolism (VTE) in a prospective observational cohort study. We measured platelet surface P-selectin, activated glycoprotein (GP) IIb/IIIa and monocyte-platelet aggregate (MPA) formation in vivo and platelet response to ex vivo stimulation with agonists of protease-activated receptor (PAR) -1, -4, and GPVI, by whole blood flow cytometry, before beginning of chemotherapy and repeatedly during the first six months thereafter (total number of samples analysed: 230)...
October 20, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27760972/-a-case-of-synchronous-multiple-metastases-in-which-the-origin-could-not-be-identified-by-routine-examination
#8
Ryo Fujiwara, Mitsuhiro Narita, Susumu Kageyama, Akihiro Kawauchi, Takahisa Nakayama, Natsumi Nishi, Hiroyuki Sugihara, Yusaku Okada
A 67-year-old man presented at our hospital with severe edema on the left side of his neck, chest and brachial regions. He had a history of right radical nephrectomy due to renal cell carcinoma (RCC, clear cell subtype, stage II) 15 years earlier. Thereafter, metastases to the pancreatic tail and right lung, and left lung metastasis were removed at 8 years and 11 years, respectively, after the nephrectomy. Four years earlier, he had also undergone total gastrectomy for gastric carcinoma (poorly differentiated adenocarcinoma, stage IV) and subsequent maintenance chemotherapy for gastric carcinoma...
September 2016: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/27756228/drug-discovery-using-clinical-outcome-based-connectivity-mapping-application-to-ovarian-cancer
#9
Rama Raghavan, Stephen Hyter, Harsh B Pathak, Andrew K Godwin, Gottfried Konecny, Chen Wang, Ellen L Goode, Brooke L Fridley
BACKGROUND: Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death among women in the United States (5 % of cancer deaths). The standard treatment for patients with advanced EOC is initial debulking surgery followed by carboplatin-paclitaxel combination chemotherapy. Unfortunately, with chemotherapy most patients relapse and die resulting in a five-year overall survival around 45 %. Thus, finding novel therapeutics for treating EOC is essential. Connectivity Mapping (CMAP) has been used widely in cancer drug discovery and generally has relied on cancer cell line gene expression and drug phenotype data...
October 19, 2016: BMC Genomics
https://www.readbyqxmd.com/read/27735949/a-metabolic-synthetic-lethal-strategy-with-arginine-deprivation-and-chloroquine-leads-to-cell-death-in-ass1-deficient-sarcomas
#10
Gregory R Bean, Jeff C Kremer, Bethany C Prudner, Aaron D Schenone, Juo-Chin Yao, Matthew B Schultze, David Y Chen, Munir R Tanas, Douglas R Adkins, John Bomalaski, Brian P Rubin, Loren S Michel, Brian A Van Tine
Sarcomas comprise a large heterogeneous group of mesenchymal cancers with limited therapeutic options. When treated with standard cytotoxic chemotherapies, many sarcomas fail to respond completely and rapidly become treatment resistant. A major problem in the investigation and treatment of sarcomas is the fact that no single gene mutation or alteration has been identified among the diverse histologic subtypes. We searched for therapeutically druggable targets that are common to a wide range of histologies and hence could provide alternatives to the conventional chemotherapy...
October 13, 2016: Cell Death & Disease
https://www.readbyqxmd.com/read/27720129/increased-acute-mortality-with-chemoradiotherapy-for-locally-advanced-head-and-neck-cancer-in-patients-%C3%A2-70years
#11
Tobin J Strom, Arash O Naghavi, Andy M Trotti, Jeffery Russell, Julie A Kish, Judith McCaffrey, Kristen J Otto, Louis B Harrison, Jimmy J Caudell
PURPOSE: Concurrent chemoradiotherapy (CRT) is the standard of care for many sites of locally advanced head and neck squamous cell carcinomas (LAHNC). However, on meta-analysis, the addition of chemotherapy did not improve survival for patients >70years. We hypothesized that elderly patients treated with CRT would have increased toxicity without similar improvements in survival. METHODS: A single-institution, IRB-approved retrospective study took place from 2005 to 2012 including 369 patients treated with CRT for LAHNC...
October 3, 2016: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/27659357/usefulness-of-chemoradiotherapy-for-inoperable-gastric-cancer
#12
T Taki, Y Hoya, A Watanabe, T Nakayoshi, T Okamoto, H Sekine, N Mitsumori, K Yanaga
Introduction Radiotherapy is not commonly used for the treatment of gastric cancer in Japan, where surgery is the standard local treatment. We report the results of chemoradiotherapy in patients with advanced or recurrent gastric cancer which was deemed difficult to treat surgically. Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed...
September 23, 2016: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/27650843/paradox-of-prescribing-late-chemotherapy-oncologists-explain
#13
Minnie Bluhm, Cathleen M Connell, Raymond G De Vries, Nancy K Janz, Kathleen E Bickel, Maria J Silveira
PURPOSE: The value of chemotherapy for patients with cancer in the last weeks of life warrants examination. Late chemotherapy may not improve survival or quality of life but typically precludes hospice enrollment and may result in additional symptoms, increased use of other aggressive treatments, and worsening quality of life. Few studies have explored oncologists' rationales for administering chemotherapy near death. This study examines the self-reported factors that influence oncologists' decisions about late chemotherapy...
September 20, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27646519/doxorubicin-loaded-70-150%C3%A2-%C3%AE-m-microspheres-for-liver-dominant-metastatic-breast-cancer-results-and-outcomes-of-a-pilot-study
#14
Yen-Ting Lin, Jacques Médioni, Grégory Amouyal, Carole Déan, Marc Sapoval, Olivier Pellerin
PURPOSE: Patients with breast cancer liver metastasis have a poor prognosis. Local therapy for liver metastasis increases survival. The purpose of this pilot prospective study was to evaluate the efficacy and safety of doxorubicin drug-eluting beads chemoembolization for liver-dominant breast cancer metastasis (LdBM) refractory to chemotherapy. MATERIALS AND METHODS: All patients with LdBM refractory to of two or more lines of systemic chemotherapy were screened...
September 19, 2016: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27626514/end-of-life-care-in-patients-with-metastatic-lung-cancer-harboring-epidermal-growth-factor-receptor-mutations
#15
Jessica R Bauman, Zofia Piotrowska, Alona Muzikansky, Emily Gallagher, Emily Scribner, Brandon Temel, Lecia V Sequist, Rebecca S Heist, Jennifer S Temel
BACKGROUND/OBJECTIVE: Patients with metastatic nonsmall cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations benefit from improved survival and quality of life with EGFR-directed therapy. We sought to explore if these improvements in cancer care impacted the delivery of end-of-life (EOL) care in this population. DESIGN: We retrospectively reviewed medical records of patients cared for at our institution with the diagnosis of metastatic EGFR-mutant NSCLC who died by January 2015...
December 2016: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/27619939/postoperative-complications-and-long-term-survival-after-complex-cancer-resection
#16
Hari Nathan, Huiying Yin, Sandra L Wong
BACKGROUND: Recent attention has focused on the ability to rescue patients from postoperative complications and prevent short-term mortality. However, it is unknown whether patients rescued from complications after complex cancer resections have long-term survival outcomes similar to those of patients without complications. METHODS: From 2005 to 2009 Surveillance, Epidemiology, and End Results (SEER)-Medicare data, the study identified elderly patients who underwent resection for cancers of the esophagus, lung, or pancreas...
September 12, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27607585/exploratory-analysis-of-ercc2-dna-methylation-in-survival-among-pediatric-medulloblastoma-patients
#17
Emilyn Banfield, Austin L Brown, Erin C Peckham, Surya P Rednam, Jeffrey Murray, M Fatih Okcu, Laura E Mitchell, Murali M Chintagumpala, Ching C Lau, Michael E Scheurer, Philip J Lupo
AIM: Medulloblastoma is the most frequent malignant pediatric brain tumor. While survival rates have improved due to multimodal treatment including cisplatin-based chemotherapy, there are few prognostic factors for adverse treatment outcomes. Notably, genes involved in the nucleotide excision repair pathway, including ERCC2, have been implicated in cisplatin sensitivity in other cancers. Therefore, this study evaluated the role of ERCC2 DNA methylation profiles on pediatric medulloblastoma survival...
October 2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/27583028/strategies-to-modulate-the-immune-system-in-breast-cancer-checkpoint-inhibitors-and-beyond
#18
REVIEW
Cristina Migali, Monica Milano, Dario Trapani, Carmen Criscitiello, Angela Esposito, Marzia Locatelli, Ida Minchella, Giuseppe Curigliano
Is breast cancer (BC) immunogenic? Many data suggest that it is. Many observations demonstrated the prognostic role of tumor-infiltrating lymphocytes (TILs) in triple negative (TN) and human epidermal growth factor receptor 2 (HER-2)-positive BC. TNBCs are poorly differentiated tumors with high genetic instability and very high heterogeneity. This heterogeneity enhances the 'danger signals' and select clone variants that could be more antigenic or, in other words, that could more strongly stimulate a host immune antitumor response...
September 2016: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/27573661/hiv-infection-and-survival-among-women-with-cervical-cancer
#19
Scott Dryden-Peterson, Memory Bvochora-Nsingo, Gita Suneja, Jason A Efstathiou, Surbhi Grover, Sebathu Chiyapo, Doreen Ramogola-Masire, Malebogo Kebabonye-Pusoentsi, Rebecca Clayman, Abigail C Mapes, Neo Tapela, Aida Asmelash, Heluf Medhin, Akila N Viswanathan, Anthony H Russell, Lilie L Lin, Mukendi K A Kayembe, Mompati Mmalane, Thomas C Randall, Bruce Chabner, Shahin Lockman
PURPOSE: Cervical cancer is the leading cause of cancer death among the 20 million women with HIV worldwide. We sought to determine whether HIV infection affected survival in women with invasive cervical cancer. PATIENTS AND METHODS: We enrolled sequential patients with cervical cancer in Botswana from 2010 to 2015. Standard treatment included external beam radiation and brachytherapy with concurrent cisplatin chemotherapy. The effect of HIV on survival was estimated by using an inverse probability weighted marginal Cox model...
August 29, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27569442/comparison-of-mapie-versus-map-in-patients-with-a-poor-response-to-preoperative-chemotherapy-for-newly-diagnosed-high-grade-osteosarcoma-euramos-1-an-open-label-international-randomised-controlled-trial
#20
Neyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, Mark Bernstein, Gordana Jovic, Mark D Krailo, Jane M Hook, Carola Arndt, Henk van den Berg, Bernadette Brennan, Bénédicte Brichard, Ken L B Brown, Trude Butterfass-Bahloul, Gabriele Calaminus, Heike E Daldrup-Link, Mikael Eriksson, Mark C Gebhardt, Hans Gelderblom, Joachim Gerss, Robert Goldsby, Allen Goorin, Richard Gorlick, Holcombe E Grier, Juliet P Hale, Kirsten Sundby Hall, Jendrik Hardes, Douglas S Hawkins, Knut Helmke, Pancras C W Hogendoorn, Michael S Isakoff, Katherine A Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C Lau, Patrick J Leavey, Stephen L Lessnick, Leo Mascarenhas, Paul A Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Papai, R Lor Randall, Peter Reichardt, Marleen Renard, Akmal Ahmed Safwat, Cindy L Schwartz, Michael C G Stevens, Sandra J Strauss, Lisa Teot, Mathias Werner, Matthew R Sydes, Jeremy S Whelan
BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation...
October 2016: Lancet Oncology
keyword
keyword
67076
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"